The National Pharmaceutical Pricing Authority (NPPA) has released the revised calculation sheet for the ceiling price of azithromycin 250 mg tablet following a review order from the Department of ...
An extended course of low-dose azithromycin (multiple brands) may significantly reduce treatment failure in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (COPD) ...
Epidemiologic, laboratory, animal, and clinical studies suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis. We evaluated the efficacy of one year of ...
May 24, 2011 (Denver, Colorado) — The addition of daily azithromycin to conventional treatment for chronic obstructive pulmonary disease (COPD) significantly helps reduce acute exacerbations ...
Azithromycin can cause side effects that range from mild to serious. More common side effects include nausea, vomiting, and abdominal pain. If azithromycin’s side effects become difficult to tolerate, ...
Depending on its form, Medicare Part D or Original Medicare may cover azithromycin. People enrolled in Part C will get the same coverage. Azithromycin (Zithromax) is an antibiotic that doctors often ...
The guideline from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) does not recommend antibiotics for prevention of COPD exacerbations. Citing decades-old data on the lack of ...
BOS may be the result of immunologic injury targeting both endothelial and epithelial tissues in the pulmonary system, and such immunologic damage may represent cGVHD, or can be induced and aggravated ...
Azithromycin has replaced clindamycin oral suspension for prophylaxis against IE in children. Patient compliance with azithromycin should be good as it only needs to be taken once a day for 3 days.
Azithromycin was effective for the treatment for women with Ureaplasma urealyticum, showing a similar therapeutic effect to that of doxycycline. Results of a systematic review and meta-analysis ...
Mass distribution of azithromycin to children 1 to 59 months of age has been shown to reduce childhood all-cause mortality in some sub-Saharan African regions, with the largest reduction seen among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results